## Distribution: As Appendix 1

From: Dr Frank Atherton, Chief Medical Officer for Wales

Date: 12 February 2021

Reference: CEM/CMO/2021/9

- Category: Immediate (cascade within 24 hours)
- Title: Colchicine In The Management Of Covid-19 (Sars-Cov 2) Positive Patients Trial Use Only

Dear colleagues,

Colchicine should not be used in the management of COVID-19 positive patients other than in the context of a trial, or unless there is an additional licensed indication for its use

Yours sincerely

**DR FRANK ATHERTON** 

To: Health Boards and NHS Trusts:

Chief Executives Medical Directors for onward distribution to: Hospital Doctors

Nurse Directors Hospital Principals and Chief Pharmacists Directors of Public Health

To: NHS Wales Shared Services Partnership to forward to:

All General Practitioners

Community Pharmacies.

HB Prescribing Advisers.

Cc: Public Health Wales:

Chief Executive Director of Public Health Services Consultants in Communicable Disease Control Microbiologists Consultant Epidemiologists Vaccine Preventable Disease Programme

Cc: NHS Direct Wales British Medical Association Royal College of GPs Royal College of Physicians Academy of Medical Royal Colleges Royal College of Nursing Royal College of Midwives Royal College of Paediatrics and Child Health Wales